Company intelligence / Profile preview

C&C Research Laboratories

Gwacheon-si, Gyeonggi-do, South Koreacnclab.co.kr ↗

Ownership: Private
Development stage: Phase 1

Overview

C&C Research Laboratories has developed multiple innovative small molecule drug candidates targeting oncology and immunology indications. Notable achievements include preclinical compounds for prostate cancer targeting XBP1s, atopic dermatitis, gout, colorectal cancer, leukemia, and more. The company leverages its CLOVER platform to accelerate discovery using AI-driven approaches. Some assets have advanced into clinical development through partnerships.

Therapeutic areas: OncologyDermatologyImmunology
Modalities: Small moleculeChemical drug
Industry: Biotech

Drug pipeline

1 asset

CNC-01

Preclinical

Partnerships

Chugai Pharmaceutical/Roche GroupAcademic collaborations

Beyond the preview

Go deeper on C&C Research Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C&C Research Laboratories.

Explore the full profile